Long-Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine
- PMID: 38683278
- DOI: 10.1007/s11916-024-01259-x
Long-Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine
Abstract
Purpose of review: Calcitonin gene-related peptide (CGRP)-targeting agents are potential candidates for disease-modifying migraine drugs. However, most studies on CGRP-targeting agents have assessed efficacy outcomes rather than long-term effects after discontinuation. This review aimed to synthesize and scrutinize the latest clinical data on the outcomes after the discontinuation of CGRP-targeting therapy in patients with episodic and chronic migraine, with a particular focus on chronic migraine.
Recent findings: Real-world studies involving patients with migraine have reported consistent findings of worsened headache frequency and quality of life after the discontinuation of CGRP monoclonal antibodies (CGRP mAbs). Although many patients maintain improvements for up to 4 months after discontinuation compared to baseline (before starting CGRP mAbs), no studies have evaluated the effects of stopping treatment for > 5 months, which is the five-half-life of CGRP mAbs. Several studies have suggested that patients treated with CGRP receptor mAbs experience more rapid deterioration than those treated with CGRP ligand mAbs after discontinuing CGRP mAbs. The results of real-world studies suggest that for many patients with migraine, the benefits of CGRP mAbs diminish months after discontinuation. Therefore, anti-CGRP therapies may not be considered disease-modifying. However, the comprehensive assessment of the disease-modifying potential of these drugs requires studies with extended treatment and cessation durations.
Keywords: CGRP-targeting therapy; Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs); Chronic migraine; Discontinuation; Disease-modifying migraine drug (DMMD).
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.J Neurol. 2024 May;271(5):2605-2614. doi: 10.1007/s00415-024-12192-9. Epub 2024 Feb 12. J Neurol. 2024. PMID: 38342785 Free PMC article.
-
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies.J Headache Pain. 2021 Dec 31;22(1):158. doi: 10.1186/s10194-021-01368-7. J Headache Pain. 2021. PMID: 34972502 Free PMC article.
-
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.Rev Neurol (Paris). 2020 Dec;176(10):788-803. doi: 10.1016/j.neurol.2020.04.027. Epub 2020 Aug 2. Rev Neurol (Paris). 2020. PMID: 32758365 Review.
-
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.J Headache Pain. 2024 Feb 2;25(1):14. doi: 10.1186/s10194-024-01721-6. J Headache Pain. 2024. PMID: 38308209 Free PMC article.
-
The sense of stopping migraine prophylaxis.J Headache Pain. 2023 Feb 16;24(1):9. doi: 10.1186/s10194-023-01539-8. J Headache Pain. 2023. PMID: 36792981 Free PMC article. Review.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
-
- Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80. - DOI
-
- Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(5 Supplement 1):S3–7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials